Key Analysts at Piper Jaffray Didn’t Change their ‘”Buy”’ rating for Argenx Se (ARGX) Shares Today. Their Target Price per Share Given is $130.0000

June 21, 2018 - By Vivian Park

Argenx Se (ARGX) Rating Reaffirmed

In an analyst note revealed this morning, Piper Jaffray reiterated their “Buy” rating on Argenx Se (ARGX) shares. The PT suggests a possible upside of 43.77 % from firm’s last stock close price.

argenx SE (NASDAQ:ARGX) Ratings Coverage

Among 3 analysts covering argenx SE – American Depositary Shares (ARGX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. argenx SE – American Depositary Shares has $13000 highest and $92 lowest target. $115.67’s average target is 27.93% above currents $90.42 stock price. argenx SE – American Depositary Shares had 4 analyst reports since April 9, 2018 according to SRatingsIntel. On Thursday, June 7 the stock rating was maintained by Piper Jaffray with “Buy”. The rating was maintained by Wedbush on Thursday, April 26 with “Outperform”. The rating was maintained by Piper Jaffray on Tuesday, June 19 with “Buy”.

The stock decreased 2.90% or $2.7 during the last trading session, reaching $90.42. About 250,328 shares traded or 123.02% up from the average. argenx SE (ARGX) has risen 340.78% since June 21, 2017 and is uptrending. It has outperformed by 328.21% the S&P500.

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody therapies for the treatment of autoimmune diseases and cancer. The company has market cap of $2.96 billion. The companyÂ’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It currently has negative earnings. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia.

More notable recent argenx SE (NASDAQ:ARGX) news were published by: 247Wallst.com which released: “Biopharma Companies to Watch This Week and for the Rest of June” on June 09, 2018, also Seekingalpha.com with their article: “Argenx’s efgartigimod shows encouraging action in mid-stage pemphigus vulgaris study” published on June 20, 2018, Streetinsider.com published: “argenx SE (ARGX) PT Raised to $130 at Piper Jaffray Following Model Adjustments” on June 07, 2018. More interesting news about argenx SE (NASDAQ:ARGX) were released by: Nasdaq.com and their article: “argenx to host KOL breakfast symposium on immune thrombocytopenia on June 19, 2018” published on June 12, 2018 as well as Benzinga.com‘s news article titled: “23 Stocks Moving In Thursday’s Pre-Market Session” with publication date: June 14, 2018.

argenx SE (NASDAQ:ARGX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: